Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Exclusion Criteria

• •1. Diagnosis of acute promyelocytic leukemia;
• •2. History or presence of a CNS disorder;
• •3. HBsAg is positive; HCV #HIV or Syphilis antibody are positive, CMV-DNA in peripheral blood is more than≥500 copies /mL;
• •4. History of severe hypersensitivity reaction;
• •5. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment;
• •6. History of organ transplant surgery;
• •7. Required systemic application of immunosuppressive or other drugs;
• •8. Auto-SCT within the 3 months before enrollment;
• •9. Active autoimmune or inflammatory diseases of the nervous system (e.g., Guillain-Barre syndrome (GBS), amyotrophic lateral sclerosis (ALS)) and clinically active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (PRES));
• •10. Requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (TLS)) ;
• •11. Presence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management;
• •12. Live vaccine received within the ≤ 4 weeks before enrollment;
• •13. Persons with serious mental illness;
• •14. History of major surgical operations four weeks before enrollment;
• •15. History of alcoholism or substance abuse;
• •16. Was identified by the investigators as unsuitable to participate in the study.